Medaphor Group PLC Notice of Results (5955G)
March 05 2018 - 1:00AM
UK Regulatory
TIDMMED
RNS Number : 5955G
Medaphor Group PLC
05 March 2018
5 March 2018
MedaPhor Group plc
("MedaPhor" or the "Company")
Notice of Results
Investor results presentation
MedaPhor Group plc (AIM: MED), the intelligent ultrasound
software and simulation company, announces it will be reporting its
final results for the year ended 31 December 2017 on Wednesday, 21
March 2018.
Investor briefing
Stuart Gall (CEO), Wilson Jennings (FD) and Nicholas Sleep (CTO)
will be hosting a briefing for investors on Wednesday, 21 March
from 3.30pm to 5pm at the offices of IP Group. There will be an
opportunity to see live demonstrations of a number of MedaPhor's
products, including ScanTrainer, HeartWorks and the newly launched
BodyWorks simulator platforms, as well as demonstrations of the new
ScanNav technology currently under development.
To register to attend for the event and for further details,
please contact Walbrook PR on 020 7933 8780 or
medaphor@walbrookpr.com.
For further information, please contact:
Walbrook PR Tel: +44 (0)20 7933 8780 or
medaphor@walbrookpr.com
Paul McManus / Anna Mob: +44 (0)7980 541 893 /
Dunphy Mob: +44 (0)7876 741 001
About MedaPhor (investors.medaphor.com)
MedaPhor (AIM: MED), the intelligent ultrasound software and
simulation company, develops artificial intelligence-based clinical
image analysis software tools, augmented reality-based needle
guidance software and advanced hi-fidelity haptic and manikin-based
training simulators for medical practitioners.
Based in Cardiff and Oxford in the UK and Atlanta in the US,
MedaPhor is split into two divisions:
Intelligent Ultrasound Simulation and Training
Focuses on hi-fidelity ultrasound education and training through
simulation. Its three main products are the ScanTrainer OBGYN and
General Medical simulator training platform, the HeartWorks
Echocardiography simulator platform and BodyWorks Eve the Point of
Care Ultrasound (PoCUS) simulator. Over 500 MedaPhor simulators
have been sold to over 300 medical institutions in over 30
countries around the world.
Intelligent Ultrasound Clinical Support
Focuses on augmented reality and deep-learning based algorithms
to make ultrasound machines smarter and more accessible. Products
in development include ScanNav which uses machine-learning based
algorithms to automatically identify and grade ultrasound images to
provide scan assessment and audit of obstetric scanning.
NeedleGuide aims to simplify ultrasound-guided needling by using
deep learning and augmented reality to provide the user with
pathway guidance and automated tracking for a range of medical
procedures.
Some products in the pipeline may require US FDA approval, as
such this material should be considered informational only and does
not constitute an offer to sell, or infer, claims or benefits.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORQLLFBVXFFBBQ
(END) Dow Jones Newswires
March 05, 2018 02:00 ET (07:00 GMT)
Intelligent Ultrasound (LSE:IUG)
Historical Stock Chart
From Apr 2024 to May 2024
Intelligent Ultrasound (LSE:IUG)
Historical Stock Chart
From May 2023 to May 2024